A physician-based study to assess the prevalence, current treatment standards, and therapy need gaps in the management of irritable bowel syndrome in India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20222976Keywords:
Irritable bowel syndrome, Mebeverine, Probiotics, Anxiety, ChlordiazepoxideAbstract
Background: Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder that can significantly affect quality of life. A physician-based survey was conducted to understand the prevalence, current treatment strategies, and gaps in IBS management in India.
Methods: A total of 197 physicians participated to complete a questionnaire comprising 36 questions related to the prevalence and current treatment of IBS and assess gaps in its management.
Results: Most physicians take a detailed history of the IBS syndrome and association-driven criteria to diagnose IBS. Most physicians reported that >50% of the patients had IBS mixed with anxiety, and most patients with IBS suffered for 2-4 weeks before seeking medical consultation. Most respondents reported that IBS patients took home remedies before consultation. Respondents ranked mebeverine plus chlordiazepoxide, followed by mebeverine monotherapy as preferred treatment for management of IBS symptoms. Mebeverine plus chlordiazepoxide was most preferred for IBS patients with anxiety. More than 70 % of physicians reported that mebeverine and its combination with chlordiazepoxide were efficacious with no adverse events for all subtypes of IBS. Most physicians prescribed probiotics with multiple strains for 2-4 weeks in patients with IBS.
Conclusions: IBS is a common gastrointestinal disorder with no apparent diagnosis and management. The survey findings support the use of mebeverine therapy for the management of IBS symptoms.
References
Bonetto S, Fagoonee S, Battaglia E, Grassini M, Saracco GM, Pellicano R. Recent advances in the treatment of irritable bowel syndrome. Pol Arch Intern Med. 2021;131:709-15.
Chey WD. Irritable Bowel Syndrome. Gastroenterol Clin North Am. 2021;50:15-6.
Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterology & Motility 2008;20:121-9.
Minocha A, Johnson WD, Abell TL, Wigington WC. Prevalence, Sociodemography, and QualitLife of Older Versus Younger Patients with Irritable Bowel Syndrome: A Population-Based Study. Digestive Dis Sci. 2006;51:446-53.
Hungin APS, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Alimentary Pharmacol Therap. 2005;21:1365-75.
Ghoshal UC, Abraham P, Bhatt C, Choudhuri G, Bhatia SJ, Shenoy KT, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2008.;27:22-8.
Makharia GK, Verma AK, Amarchand R, Goswami A, Singh P, Agnihotri A, et al. Prevalence of Irritable Bowel Syndrome: A Community Based Study From Northern India. J Neurogastroenterol Motility. 2011;17:82-7.
Gwee K-A, Bak Y-T, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25:1189-205.
Cassar GE, Youssef J G, Knowles SR, Moulding R, Austin D. The Impact of Diagnostic Status on Quality of Life in Irritable Bowel Syndrome. Turkish J Gastroenterol. 2021;32:808-18.
Goodoory VC, Mikocka-Walus A, Yiannakou Y, Houghton LA, Black CJ, Ford AC. Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:1485-94.
Sibelli A, Chalder T, Everitt H, Workman P, Windgassen S, Moss-Morris R. A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol Med. 2016;46:3065-80.
Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Alimentary Pharmacol Therap. 2019;50:132-43.
Chey WD, Kurlander J, Eswaran S. Irritable Bowel Syndrome. JAMA. 2015;313:949.
Drossman DA. Rome III: The new criteria. Chinese J Digestive Dis. 2006;7:181-5.
Lacy B, Patel N. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6:99.
Zhou S, Liu X, Wang X, Xi F, Luo X, Yao L, et al. Pharmacological and non-pharmacological treatments for irritable bowel syndrome. Medicine. 2019;98:e16446.
Rawla P, Sunkara T, Raj JP. Updated review of current pharmacological and non-pharmacological management of irritable bowel syndrome. Life Sciences. 2018;212:176-81.
Collins J, Farrall E, Turnbull DA, Hetzel DJ, Holtmann G, Andrews JM. Do We Know What Patients Want? The Doctor-Patient Communication Gap in Functional Gastrointestinal Disorders. Clin Gastroenterol Hepatol. 2009;7:1252-4.
Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16:547-53.
Anthoine E, Moret L, Regnault A, Sébille V, Hardouin JB. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12:176.
Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Alimentary Pharmacol Therap. 2015;42:491-503.
Palsson OS, Whitehead WE, van Tilburg MAL, Chang L, Chey W, Crowell MD, et al. Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology. 2016;150:1481-91.
Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97:2812-9.
Bijkerk CJ, Wit NJ de, Stalman WA, Knottnerus JA, Hoes AW, Muris JW. Irritable Bowel Syndrome in Primary Care: The Patients' and Doctors' Views on Symptoms, Etiology and Management. Canad J Gastroenterol. 2003;17:363-8.
Casiday RE, Hungin APS, Cornford CS, de Wit NJ, Blell MT. Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology. Fam Pract. 2008;26:40-7. [
Niknam R, Mousavi S, Safarpour A, Mahmoudi L, Mahmoudi P. Self-medication of irritable bowel syndrome and dyspepsia: How appropriate is it? J Res Pharm Pract. 2016;5:121.
Barry CA. Patients' unvoiced agendas in general practice consultations: qualitative study. BMJ. 2000;320:1246-50.
Paterson WG, Thompson WG, Vanner SJ, Faloon TR, Rosser WW, Birtwhistle RW, et al. Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants. CMAJ. 1999;161:154-60.
Defrees DN, Bailey J. Irritable Bowel Syndrome. Primary Care: Clinics in Office Practice. 2017;44:655-71.
Törnblom H, Drossman DA. Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders. Curr Gastroenterol Rep. 2018;20:58.
Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Alimentary Pharmacol Therap. 2001;15:355-61.
Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Alimentary Pharmacol Therap. 2007;8:499-510.
Jailwala J. Pharmacologic Treatment of the Irritable Bowel Syndrome. Ann Int Med. 2000;133:136.
Winsemius A, Meuwsen IM, Boon C, van der Laan A, Brekle A, de Vries M. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002;56:659-62.
Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H, et al. Quality of Life in Patients with Irritable Bowel Syndrome (IBS), Assessed Using the IBS–Quality of Life (IBS-QOL) Measure After 4 and 8 Weeks of Treatment with Mebeverine Hydrochloride or Pinaverium Bromide: Results of an International Prospective Observational Cohort Study in Poland, Egypt, Mexico and China. Clinical Drug Investigation. 2014;34:783-93.
Hetterich L, Stengel A. Psychotherapeutic Interventions in Irritable Bowel Syndrome. Front Psychiatry 2020;11.
Halpert A. Irritable Bowel Syndrome: Patient-Provider Interaction and Patient Education. J Clin Med. 2018;7:3.
Fan YJ, Chen SJ, Yu YC, Si JM, Liu B. A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. J Zhejiang Univ Sci B. 2006;7:987-91.
Kim J, Cho K, Kim JS, Jung HC, Kim B, Park MS, et al. Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial. Food Sci Biotechnol. 2020;29:837-44.
